Annovis Bio Granted NYSE Compliance Extension for Neurodegenerative Therapies
Annovis Bio receives NYSE compliance extension, continuing its mission to develop neurodegenerative disease therapies. Learn more about their innovative approach.
This news is significant for investors and patients alike, as Annovis Bio's work in developing treatments for Alzheimer’s and Parkinson’s diseases represents a beacon of hope for millions affected by these conditions. The NYSE's compliance extension ensures the company can continue its critical research without operational disruptions, potentially accelerating the availability of groundbreaking therapies.
